摘要
目的探讨18F-脱氧葡萄糖(18F-FDG)符合线路正电子显像在非小细胞肺癌(NSCLC)治疗前临床分期中的价值。方法39例NSCLC患者在治疗前行18F-FDG符合线路正电子显像,并进行符合线路显像分期,将符合线路显像分期和CT分期结果进行比较。结果18F-FDG符合线路显像使18例(46.15%,18/39)的临床总分期发生改变,均为分期升级,其中11例的治疗策略发生改变,由根治性手术治疗变为姑息性放疗或化疗。18F-FDG符合线路显像对NSCLC总分期的改变主要是通过对N和M分期的改变而实现的。结论18F-FDG符合线路显像改变了46.15%(18/39)NSCLC患者的临床分期,影响了28.20%(11/39)的治疗策略。18F-FDG符合线路显像在NSCLC治疗前分期中有重要的参考价值。
Objective To evaluate the value of ^18F-deoxyglucose （18F_FDG） coincidence SPECT in clinical staging of nonsmall cell lung cancer （NSCLC） before treatment. Methods Thirty-nine patients with NSCLC had been examined by ^18F-FDG coincidence SPECT and staged by SPECT before treatment. The results of ^18F-FDG coincidence SPECT examination were compared with those of CT. Results The staging was upstaged in 18 patients because of ^18F-FDG coincidence SPECT finding. The treatment strategy bad been changed in 11 patients with NSCLC. The changing of clinical TNM staging mainly depended on changing of N or M sub-staging by ^18F-FDG coincidence SPECT. Conclusion ^18F-FDG coincidence SPECT has an important value on treatment strategy in NSCLC patients by changing clinical staging.
出处
《中国医学影像技术》
CSCD
北大核心
2006年第11期1749-1751,共3页
Chinese Journal of Medical Imaging Technology
